Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Indication

Prostate Cancer

Clinical and regulatory intelligence for Prostate Cancer with 10 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
10
Catalysts
0
Assets
7

Relevant assets

Flutamide →
Oncology →
QLC5508 →
TALZENNA →
Truqap →
Ubiquitination →
Xaluritamig →

Relevant companies

Amgen →
AstraZeneca →
Bayer →
Pfizer →
QLC Biotech →
Roche →

Recent signals(10)

ClinicalJune 21, 2026

Ubiquitination signature identified in neuroendocrine prostate cancer with therapeutic implications

A ubiquitination-centered signature linked to neuroendocrine prostate cancer (NEPC) was identified, highlighting its role in lineage plasticity.

ClinicalJune 19, 2026

Amgen's Xaluritamig Plus Abiraterone Trial Targets Metastatic Prostate Cancer

Amgen is conducting a trial to compare overall survival in patients with metastatic castration-resistant prostate cancer receiving xaluritamig plus abiraterone versus standard treatments.

ClinicalJune 18, 2026

Phase Ib/II Trial of QLC5508 and QLH12016 in Advanced Prostate Cancer

A Phase Ib/II clinical trial is underway to evaluate QLC5508 and QLH12016 in combination with other therapies for advanced prostate cancer.

ClinicalJune 17, 2026

Study on Exercise Program's Impact on Quality of Life in Prostate Cancer Patients

A clinical trial is assessing the effects of a structured exercise program on quality of life and health outcomes in prostate cancer patients.

ClinicalJune 17, 2026

Gut Microbiota Impairs Flutamide Efficacy in Prostate Cancer Treatment

Gut bacteria metabolize Flutamide into inactive forms, reducing its therapeutic efficacy against prostate cancer.

ClinicalJune 17, 2026

Trial Evaluates Pelvic Radiotherapy with ADT in Node Positive Prostate Cancer

A clinical trial is assessing the efficacy of adding pelvic radiotherapy to androgen deprivation therapy in patients with node-positive prostate cancer post-prostatectomy.

RegulatoryJune 16, 2026

Truqap approved in US for PTEN-deficient metastatic prostate cancer

Truqap, a first-in-class AKT inhibitor, has been approved in the US for treating PTEN-deficient metastatic hormone-sensitive prostate cancer.

RegulatoryJune 16, 2026

FDA ODAC Recommends Truqap for PTEN-Deficient Prostate Cancer

The FDA ODAC has recommended Truqap in combination with abiraterone and ADT for PTEN-deficient metastatic hormone-sensitive prostate cancer.

ClinicalJune 16, 2026

TALZENNA Plus XTANDI Shows 52% rPFS Improvement in Metastatic Prostate Cancer

The Phase 3 TALAPRO-3 study demonstrated that TALZENNA plus XTANDI significantly improved radiographic progression-free survival (rPFS) by 52% in patients with HRR gene-altered metastatic prostate cancer.

RegulatoryJune 13, 2026

Roche's VENTANA PTEN Assay Receives FDA Approval for Prostate Cancer Companion Diagnostic

Roche's VENTANA PTEN (SP218) RxDx Assay is the first FDA-approved companion diagnostic for assessing PTEN protein loss in prostate cancer.

Upcoming catalysts

No catalysts indexed for this entity yet.

Therapeutic areas

Oncology →
Prostate Cancer →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.